Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Immunity Mechanism Revealed

Receptor findings could aid autoimmune disease studies

by Stuart A. Borman
February 9, 2009 | A version of this story appeared in Volume 87, Issue 6

[+]Enlarge
Credit: Proc. Natl. Acad. Sci. USA
Credit: Proc. Natl. Acad. Sci. USA

Researchers have discovered the role played by a key immune-cell coreceptor. CD22 (orange) is a coreceptor to B-cell receptors (BCRs, blue) on the surface of antibody-generating B-cells. CD22 is known to prevent immune responses. But its mechanism of action has been blocked from scientists' view because it binds to immunogenic glycoproteins with sialic acid groups, both from the surrounding medium and on its own cell surface. The cell-surface interactions tie up CD22's binding site, making it hard to study the effects of external CD22 ligands. Laura L. Kiessling and coworkers at the University of Wisconsin, Madison, have now used antigenic polymers bearing both BCR and CD22 ligands (blue circles and red squares) to promote binding of external CD22 ligands (Proc. Natl. Acad. Sci. USA, DOI: 10.1073/pnas.0807207106). They find that immunogenic ligands that bind CD22 inhibit immune activation—showing that the presence of sialic acid residues on antigens can suppress the immune response. The work could lead to new strategies to prevent autoimmune conditions like multiple sclerosis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.